不同剂量伐昔洛韦联合胸腺肽治疗带状疱疹临床效果和安全性评价.docVIP

不同剂量伐昔洛韦联合胸腺肽治疗带状疱疹的临床效果和安全性评价 　　[摘要] 目的 分析不同剂量伐昔洛韦联合胸腺肽治疗带状疱疹的临床效果和安全性。 方法 选择在杭州市余杭区妇幼保健院接受住院治疗的带状疱疹患者128例作为研究对象，随机分为使用常规剂量伐昔洛韦联合胸腺肽治疗的A组（64例）及大剂量伐昔洛韦联合胸腺肽治疗的B组（64例），观察患者接受治疗前后的水疱面积、有无新发水疱、结痂、脱痂等病情评分、疼痛评分，以及治疗过程中并发症发生率等情况。 结果 ①治疗后，两组患者水疱面积、新发水疱、结痂及脱痂情况评分均显著低于治疗前（P 0.05）；②治疗后，两组患者疼痛严重程度均低于治疗前（P 0.05）。 结论 大剂量伐昔洛韦在控制带状疱疹患者病情的同时，可以更有效地缓解患者疼痛感受，且不增加不良反应发生。 　　[关键词] 带状疱疹；伐昔洛韦；胸腺肽；安全性 　　[中图分类号] R752.12[文献标识码] A[文章编号] 1673-7210（2014）06（c）-0104-04 　　 　　Clinical effect and safety evaluation of different doses of Valaciclovir combined with thymosin in treating shingles 　　ZHANG Haipeng 　　Department of Dermatology, Yuhang District Maternal and Child Care Service Centre, Zhejiang Province, Hangzhou 311000, China 　　[Abstract] Objective To analyze the effect and safety of different doses of Valaciclovir combined with thymosin in treating shingles. Methods 128 cases of patients with shingles in Yuhang District Maternal and Child Care Service Centre were enrolled as research subjects and randomly divided into 64 cases of group A who received conventional dose of Valaciclovir combined with thymosin and 64 cases of group B who received high-dose of Valaciclovir combined with thymosin. Then blisters area, new blisters number, scab, scab off, pain score and the incidence of complications were observed. Results ①After treatment, the disease severity of two groups were lower than those before treatment (P 0.05); ②after treatment, the pain severity of two groups were lower than those before treatment (P 0.05). Conclusion High-dose of Valaciclovir combined with thymosin can control shingles and relieve pain feelings, without increasing the incidence of adverse reactions. 　　[Key words] Shingles; Valaciclovir; Thymosin; Safety 　　带状疱疹为水痘-带状疱疹病毒感染皮肤疾病，该病毒具有亲神经性，当患者处于劳累、感冒等免疫能力低下状态时，潜伏的病毒可迅速生长繁殖并沿神经纤维移至皮肤，最终使受侵犯的神经及皮肤产生强烈疼痛[1]。带状疱疹患者多伴有剧烈疼痛，其病程虽有自限性，但是其疼痛剧烈无法忍受，必须采取积极的治疗措施。带状疱疹患者的治疗一般为抗病毒及提高自身免疫能力，故多选择核苷类抗病毒药物与胸腺肽联合使用[2-3]。伐昔洛韦为目前临床最常用的抗病毒药物，目前对其使用剂量仍存在较大争议，部分学者认为应增加其使用剂量以迅速控制病情，但是